Search - tctmd.com

Displaying 1 - 20 of 62

Sort: Relevancy | Date

News Daily News

TCTMD’s Top 10 Most Popular Stories for December 2021

Caitlin E. Cox

December 29, 2021

News Opinion Editor's Corner

Glancing Back, Looking Forward: Lasting Lessons for Years to Come

Shelley Wood

December 27, 2021

News Features

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

Michael O'Riordan

December 23, 2021

News Daily News

Risk Factors Still Matter for Patients With Zero CAC Score: MESA

Yael L. Maxwell

December 14, 2021

News Features

Home School: Clinical Trials Went Virtual in COVID-19—Are They Here to Stay?

Todd Neale

December 09, 2021

News Daily News

Statins Underprescribed in PAD Before and After Interventions

L.A. McKeown

December 03, 2021

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

News Conference News

AXIOMATIC-TKR: Milvexian Promising for VTE Prevention

L.A. McKeown

November 15, 2021

News Conference News AHA 2021

Small CRAVE Trial Reassures on Caffeine Safety in Rhythm Disorders

L.A. McKeown

November 14, 2021

News Conference News TCT 2021

Debating ISCHEMIA: Do the Results Apply to CABG, Too?

Michael O'Riordan

November 10, 2021

News Daily News

CVD Risk ‘Underappreciated’ After Adverse Pregnancy Outcomes

L.A. McKeown

November 01, 2021

News Daily News

Only a Minority of Stable PCI Patients Meet ISCHEMIA Criteria, Study Contends

Shelley Wood

November 01, 2021

News Daily News

Nonfatal MI Not a Death Surrogate in Cardiology: Meta-analysis

Caitlin E. Cox

October 27, 2021

News Conference News TCT 2021

NSTEMI Patients With CKD See Better Outcomes With Invasive Strategy

L.A. McKeown

October 22, 2021

News Conference News EACTS 2021

More Deaths With Bioprosthetic Than Mechanical AVR in Young AS Patients

Michael O'Riordan

October 18, 2021

News Daily News

Half-Dose DOAC May Be a Good Post-Watchman Option

Todd Neale

October 14, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

Todd Neale

October 13, 2021

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

L.A. McKeown

October 12, 2021

News Daily News

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

Yael L. Maxwell

October 12, 2021

News Daily News

Cardiac Deaths and Adverse Events After PCI Have Declined With Time

L.A. McKeown

October 05, 2021

Advertisement

TCTMD’s Top 10 Most Popular Stories for December 2021

Glancing Back, Looking Forward: Lasting Lessons for Years to Come

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

Risk Factors Still Matter for Patients With Zero CAC Score: MESA

Home School: Clinical Trials Went Virtual in COVID-19—Are They Here to Stay?

Statins Underprescribed in PAD Before and After Interventions

Canagliflozin Improves Quality of Life in HF Patients

AXIOMATIC-TKR: Milvexian Promising for VTE Prevention

Small CRAVE Trial Reassures on Caffeine Safety in Rhythm Disorders

Debating ISCHEMIA: Do the Results Apply to CABG, Too?

CVD Risk ‘Underappreciated’ After Adverse Pregnancy Outcomes

Only a Minority of Stable PCI Patients Meet ISCHEMIA Criteria, Study Contends

Nonfatal MI Not a Death Surrogate in Cardiology: Meta-analysis

NSTEMI Patients With CKD See Better Outcomes With Invasive Strategy

More Deaths With Bioprosthetic Than Mechanical AVR in Young AS Patients

Half-Dose DOAC May Be a Good Post-Watchman Option

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

Cardiac Deaths and Adverse Events After PCI Have Declined With Time

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content